704 related articles for article (PubMed ID: 20145517)
1. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection.
Walsh RC; Everly JJ; Brailey P; Rike AH; Arend LJ; Mogilishetty G; Govil A; Roy-Chaudhury P; Alloway RR; Woodle ES
Transplantation; 2010 Feb; 89(3):277-84. PubMed ID: 20145517
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.
Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Tevar A; Woodle ES
Transplantation; 2008 Dec; 86(12):1754-61. PubMed ID: 19104417
[TBL] [Abstract][Full Text] [Related]
3. Case presentations on two patients who received bortezomib for antibody mediated rejection at BIDMC.
Pavlakis M
Clin Transpl; 2009; ():343-5. PubMed ID: 20524296
[TBL] [Abstract][Full Text] [Related]
4. Abrogation of anti-HLA antibodies via proteasome inhibition.
Trivedi HL; Terasaki PI; Feroz A; Everly MJ; Vanikar AV; Shankar V; Trivedi VB; Kaneku H; Idica AK; Modi PR; Khemchandani SI; Dave SD
Transplantation; 2009 May; 87(10):1555-61. PubMed ID: 19461494
[TBL] [Abstract][Full Text] [Related]
5. Lung transplantation across donor-specific anti-human leukocyte antigen antibodies: utility of bortezomib therapy in early graft dysfunction.
Stuckey LJ; Kamoun M; Chan KM
Ann Pharmacother; 2012 Jan; 46(1):e2. PubMed ID: 22202499
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitor treatment of antibody-mediated allograft rejection.
Woodle ES; Alloway RR; Girnita A
Curr Opin Organ Transplant; 2011 Aug; 16(4):434-8. PubMed ID: 21753709
[TBL] [Abstract][Full Text] [Related]
7. Proteasome inhibition reduces donor-specific antibody levels.
Everly MJ; Everly JJ; Susskind B; Brailey P; Arend LJ; Alloway RR; Roy-Chaudhury P; Govil A; Mogilishetty G; Rike AH; Cardi M; Wadih G; Brown E; Tevar A; Woodle ES
Transplant Proc; 2009; 41(1):105-7. PubMed ID: 19249489
[TBL] [Abstract][Full Text] [Related]
8. Proteasome inhibition for antibody-mediated rejection.
Everly JJ; Walsh RC; Alloway RR; Woodle ES
Curr Opin Organ Transplant; 2009 Dec; 14(6):662-6. PubMed ID: 19667989
[TBL] [Abstract][Full Text] [Related]
9. Bortezomib-based treatment of antibody mediated rejection in pancreas allograft recipients.
Govil A; Walsh RC; Tevar A; Alloway R; Roy-Chaudhury P; Mogilishetty G; Wall GE; Brailey P; Girnita A; Woodle ES
Clin Transpl; 2009; ():443-53. PubMed ID: 20524313
[TBL] [Abstract][Full Text] [Related]
10. Elimination of post-transplant donor-specific HLA antibodies with bortezomib.
Idica A; Kaneku H; Everly MJ; Trivedi HL; Feroz A; Vanikar AV; Shankar V; Trivedi VB; Modi PR; Khemchandani SI; Dave SD; Terasaki PI
Clin Transpl; 2008; ():229-39. PubMed ID: 19708459
[TBL] [Abstract][Full Text] [Related]
11. Proteasome inhibitor therapy for antibody-mediated rejection.
Woodle ES; Walsh RC; Alloway RR; Girnita A; Brailey P
Pediatr Transplant; 2011 Sep; 15(6):548-56. PubMed ID: 21884344
[TBL] [Abstract][Full Text] [Related]
12. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.
Flechner SM; Fatica R; Askar M; Stephany BR; Poggio E; Koo A; Banning S; Chiesa-Vottero A; Srinivas T
Transplantation; 2010 Dec; 90(12):1486-92. PubMed ID: 21042239
[TBL] [Abstract][Full Text] [Related]
13. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients.
Morrow WR; Frazier EA; Mahle WT; Harville TO; Pye SE; Knecht KR; Howard EL; Smith RN; Saylors RL; Garcia X; Jaquiss RD; Woodle ES
Transplantation; 2012 Feb; 93(3):319-24. PubMed ID: 22179403
[TBL] [Abstract][Full Text] [Related]
14. The fate of anti-HLA antibody among renal transplantation recipients treated with bortezomib.
Lonze BE; Dagher NN; Simpkins CE; Singer AL; Segev DL; Zachary AA; Montgomery RA
Clin Transpl; 2009; ():377-84. PubMed ID: 20524301
[TBL] [Abstract][Full Text] [Related]
15. The influence of bortezomib on donor specific antibody reduction in patients with antibody mediated rejection.
Hardinger KL; Murillo D
Clin Transpl; 2011; ():401-8. PubMed ID: 22755438
[TBL] [Abstract][Full Text] [Related]
16. Bortezomib for refractory antibody-mediated cardiac allograft rejection.
Eckman PM; Thorsgard M; Maurer D; Kim Y; Alloway RR; Woodle ES
Clin Transpl; 2009; ():475-8. PubMed ID: 20524318
[TBL] [Abstract][Full Text] [Related]
17. Proteasome inhibition with bortezomib: an effective therapy for severe antibody mediated rejection after renal transplantation.
Sureshkumar KK; Hussain SM; Marcus RJ; Ko TY; Khan AS; Tom K; Vivas CA; Parris G; Jasnosz KM; Thai NL
Clin Nephrol; 2012 Mar; 77(3):246-53. PubMed ID: 22377258
[TBL] [Abstract][Full Text] [Related]
18. Bortezomib alone fails to decrease donor specific anti-HLA antibodies: 4 case reports.
Sberro-Soussan R; Zuber J; Suberbielle-Boissel C; Legendre C
Clin Transpl; 2009; ():433-8. PubMed ID: 20524311
[TBL] [Abstract][Full Text] [Related]
19. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
[TBL] [Abstract][Full Text] [Related]
20. Antihumoral rejection therapy by proteasome inhibitor bortezomib: a case series.
Lachmann N; Schütz M; Budde K; Schönemann C; Waiser J
Clin Transpl; 2009; ():351-8. PubMed ID: 20527073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
